CLEVELAND BIOLABS INC | 2013 | FY | 3


The following table sets forth the changes in the number of warrants outstanding for the periods presented, exclusive of the warrants issued to Rusnano in connection with their loan to Panacela as those warrants are not exercisable until an event of default which has not occurred:

 

     Number of
Warrants
    Weighted Average
Exercise Price
     Number of Common
Shares Exercisable Into
 

Outstanding at December 31, 2011

     10,121,219      $ 3.76         12,564,193   

Granted

     4,312,500        3.00         4,312,500   

Forfeited, Canceled

     (4,055,724     5.07         (6,498,698
  

 

 

      

 

 

 

Outstanding at December 31, 2012

     10,377,995        2.94         10,377,995   

Granted

     156,250        1.60         156,250   
  

 

 

      

 

 

 

Outstanding at December 31, 2013

     10,534,245        2.70         10,534,245   
  

 

 

      

 

 


us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock